Navigation Links
Rigel to Present at BIO CEO & Investor Conference
Date:2/7/2013

SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower , the company's chairman and chief executive officer, is scheduled to present a company overview at the 15th Annual BIO CEO & Investor Conference in New York City on Monday, February 11th at 10:00 a.m. ET.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.

Contact: Ryan Maynard    
Phone: 650.624.1284    
Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
9. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Ten outstanding teachers in the Greater Houston area ... will win a visit by a Houston Texans player, two tickets to a Texans ... years old can visit texanschecking.com/stars to nominate their favorite teacher with an essay of ...
(Date:8/16/2017)... Georgia (PRWEB) , ... August 16, 2017 , ... ... in Atlanta, opened their doors. They celebrate 30 years in business this year, ... create an up-to-date, inviting, tranquil space to serve their patients. , It ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... ... 2017 , ... A global leader in the treatment of clubfoot, CURE ... Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong disability ... on track to enroll 10,000 children in the clubfoot treatment program in this year ...
(Date:8/16/2017)... ... ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has announced their ... a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their content will ... in 2018. Proceeds will be going to further health research. , Fusion Flix ...
Breaking Medicine News(10 mins):